{"slideshow_credits": null, "snippet": "The $2.6 billion acquisition of Medicis Pharmaceutical is the 11th deal this year for the Montreal-based Valeant, which merged with Biovail of Canada in 2010.", "abstract": "The $2.6 billion acquisition of Medicis Pharmaceutical is the 11th deal this year for the Montreal-based Valeant, which merged with Biovail of Canada in 2010.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Mark", "role": "reported", "lastname": "SCOTT", "rank": 1, "organization": ""}], "original": "By MARK SCOTT"}, "web_url": "http://dealbook.nytimes.com/2012/09/04/valeant-continues-its-string-of-acquisitions/", "lead_paragraph": null, "headline": {"main": "Valeant Sticks to Torrid Pace of Deal-Making", "kicker": "DealBook"}, "_id": "5046090a1c22dfde670b8711", "word_count": "469", "multimedia": [], "pub_date": "2012-09-04T09:51:37Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Medicis Pharmaceutical Corporation", "rank": "1"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}